Navigation Links
ISIS Reports Phase 1 Data Demonstrating ISIS-TTRRx Produces Significant Reductions in TTR Protein
Date:1/5/2012

CARLSBAD, Calif., Jan. 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today results from a Phase 1 study with ISIS-TTRRx.  The results demonstrated that treatment with ISIS-TTRRx produced dose-dependent statistically significant reductions of greater than 80 percent in transthyretin (TTR) protein.  In this study, ISIS-TTRRx was generally well tolerated with no significant adverse events.  ISIS-TTRRx is an antisense drug in development with GlaxoSmithKline (GSK) for the treatment of TTR amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.  Isis and GSK are planning to begin a clinical study on ISIS-TTRRx this year designed to achieve an efficient route to registration.

"TTR amyloidosis is a fatal disease that affects approximately 50,000 patients worldwide.  Patients with familial amyloid polyneuropathy, or FAP, experience TTR build up in their peripheral nerves and experience the loss of motor functions, such as walking.  These patients also experience the accumulation of TTR amyloid in the heart, causing familial amyloid cardiomyopathy (FAC), and in their intestinal tract, which prevents the proper absorption of nutrients, leading to death.  Since current treatments are highly limited, there is a great need to develop a drug that can reduce TTR levels thereby preventing, and potentially reversing, progression of this disease," said Merrill D. Benson, M.D., Professor of Medical Genetics at Indiana University.

"Currently the most effective way to retard progression of FAP is a liver transplant.  However, many patients with FAP are unable to receive a liver transplant due to availability of a donor liver or the patient's diminished health.  In the small number of patients who do receive a transplant, their quality of
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Reports Preliminary Fourth Quarter 2011 Esbriet® (pirfenidone) Revenue and Other Recent Business Highlights
2. Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
3. Cardium Reports on Renewed Compliance With NYSE Amex Exchange Listing Guidelines
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. Solos Endoscopy, Inc. Reports Significant Sales From Its MammoView® Instrument Line
6. VIVUS Reports Topline Findings From FORTRESS
7. Angeion Corporation Reports Fourth Quarter and Fiscal Year 2011 Operating Results
8. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
9. American Pacific Reports Fiscal 2011 Results
10. Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
11. Cantel Medical Reports 25% Increase in Net Income - EPS of $0.35 vs. $0.29 - for Quarter Ended October 31, 2011 on 30% Sales Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... has announced the addition of the "Investigation ... report to their offering. Developed by ... of Novolog) is an important drug for the ... aspart, as a fast- acting insulin analog, starts ...
(Date:8/28/2015)... 2015  IP Shakti, LLC, today announced that it has ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... corporate identity signifies our transformation into a company focused on ... for patent claim validity." ... AIA Shield™ platform, the Company commenced a corporate re-branding initiative ...
(Date:8/28/2015)... and PITTSBURGH , ... MYL ) today announced that its shareholders have ... (NYSE: PRGO ; TASE) and the related ... at an extraordinary general meeting of shareholders held ... votes cast at the extraordinary general meeting. In ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... Heska Corporation (NASDAQ: HSKA ), a provider ... , today announced that Robert Grieve, Heska,s Chairman and CEO, ... 2011 at 10:30 a.m. PT / 1:30 p.m. ET.  The ... Hotel in Los Angeles. (Logo: http://photos.prnewswire.com/prnh/20000622/HESKALOGO ) ...
... Md., Sept. 13, 2011 Sodexo, Inc., a leader ... with Healthsense, Inc.  As a part of the agreement, ... existing senior living client communities – expanding Sodexo,s current ... Life for all of the people and communities they ...
Cached Medicine Technology:Heska to Present at LD MICRO Invitational on September 22, 2011 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 2Sodexo Partners with Healthsense to Offer Seniors Technology-Enabled Solutions that Improve Quality of Daily Life 3
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic Informed Consent ... – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic ... , Clinical trial sites can now use audio, video and interactivity ...
(Date:8/29/2015)... ... 29, 2015 , ... Targeted therapies, made possible by a ... patients, according to a newly published report. Surviving Mesothelioma has more on the ... , The authors of the new paper focus on several types of targeted ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... ProDrop ... X . Each preset contains 15 seconds of unique footage that users can shrink ... rise, fall, zoom, attract and more. Users can customize color, brightness, scale, speed, range, ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health Sciences announced ... Arterosil and Arterosil HP, and that all claims and counterclaims have been irrevocably ... LLC (VHS) in the United States District Court for the Southern District of ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists are ... children helping children, a thank you to the many creative and generous ways ... the United Methodist initiative to end malaria deaths. , The Columbus Zoo and ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3
... found those with multiple auras had seizures arising from one ... People with epilepsy who experience multiple types of auras may ... arise from one area of the brain, a U.S. study ... of Neurology , ,included 31 epilepsy patients who experienced ...
... also been linked to Alzheimer,s, researchers note , FRIDAY, ... apolipoprotein E (APOE) e4 gene variant -- associated with ... types of dementia -- are more likely to develop ... gene variant, a U.S. study finds. , Researchers at ...
... The female sex hormone estrogen turns on a gene linked ... , The cancer biology team from UQ,s Diamantina Institute ... help explain the link between breast cancer and high levels ... ability of estrogen to switch this gene on is important ...
... THURSDAY, Aug. 23 (HealthDay News) -- After a heart attack, ... a new study finds. , In fact, recent heart attack ... diabetes compared with the general population and more than 15 ... the report in the Aug. 25 issue of The ...
... The smell fades with time, study shows , THURSDAY, Aug. ... can affect drinking water,s odor but not for long, a ... instead of copper piping, and scientists are trying to evaluate ... In this study, researchers evaluated several types of plastic piping. ...
... from the Sahlgrenska Academy has established that surgery reduces ... follow up has shown that mortality is significantly lower ... do not. , The results are published today ... show for the first time that surgery against obesity ...
Cached Medicine News:Health News:Some Epilepsy Patients Are Good Candidates for Surgery 2Health News:Gene Tied to Post-Op Delirium in Elderly 2Health News:Heart Attack Boosts Diabetes Risk 2Health News:Surgery for severe obesity saves lives 2
... Single Use linear stapler with LACTOMER™ ... Suture™ PREMIUM POLY CS™-57 disposable surgical ... of a temporary opening, such as ... section, or when transecting muscle tissue, ...
... Units With Titanium Staples for ... (Single Use Reloadable Stapler with ... Suture™ PREMIUM MULTIFIRE TA™ stapler ... pediatric and thoracic surgical procedures ...
... Single Use Loading Units for ... (Single Use Reloadable Staplers with ... Suture™ TA™ Reloadable staplers has ... and thoracic surgical procedures for ...
... linear stapler for resection, transection and anastomosis ... MULTIFIRE GIA™ 60 and 80 single use ... 80 single use loading units and the ... use surgical stapler with MULTIFIRE SGIA™ 60 ...
Medicine Products: